Results 261 to 270 of about 496,699 (309)
Some of the next articles are maybe not open access.
Journal of Child Neurology, 1997
The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The
openaire +2 more sources
The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The
openaire +2 more sources
Psychopharmacology and pharmacokinetics
2019The overall physiologic changes associated with aging lead to changes in both pharmacokinetic and pharmacodynamic actions of many medications. This, in turn, leads to changes in the impact that a wide variety of medications have on older adults when compared to younger, healthy individuals. These pharmacokinetic and pharmacodynamic variations can cause
Jacob, Tillmann, Ashley, Reich
openaire +2 more sources
PHARMACOKINETIC CONSIDERATIONS
Critical Care Clinics, 1999Limited studies of the pharmacokinetics of pain medication suggest altered serum elimination when the liver is hypoperfused or affected by severe cirrhosis. Drugs that are eliminated by Phase I oxidation reactions are sensitive to changes in hepatic blood flow, while drugs eliminated by Phase II glucuronidation are more affected by diseased hepatocytes.
D F, Volles, R, McGory
openaire +2 more sources
Pharmacokinetics in the elderly
European Journal of Clinical Pharmacology, 1975The pharmacokinetics of sulphamethizole, paracetamol and phenylbutazone were investigated and compared in young and geriatric subjects. The rate and extent of absorption of the drugs did not appear to be affected by increasing subject age. However, the mean half-lives for sulphamethizole and paracetamol were significantly increased in the geriatric ...
E J, Triggs +3 more
openaire +2 more sources
Journal of Neurology, 2010
This paper reviews the clinically relevant determinants of levodopa peripheral pharmacokinetics and main observed changes in the levodopa concentration-effect relationship with Parkinson's disease (PD) progression. Available clinically practical strategies to optimise levodopa pharmacokinetics and pharmacodynamics are briefly discussed.
Manuela, Contin, Paolo, Martinelli
openaire +2 more sources
This paper reviews the clinically relevant determinants of levodopa peripheral pharmacokinetics and main observed changes in the levodopa concentration-effect relationship with Parkinson's disease (PD) progression. Available clinically practical strategies to optimise levodopa pharmacokinetics and pharmacodynamics are briefly discussed.
Manuela, Contin, Paolo, Martinelli
openaire +2 more sources
Pharmacokinetics of nicorandil
The American Journal of Cardiology, 1989This report presents the findings of some studies on single intravenous and oral dosing performed in healthy volunteers to determine the pharmacokinetics and preliminary metabolism of nicorandil, a new vasodilator acting via increase of both membrane potassium conductance and intracellular cyclic guanosine monophosphate in vascular smooth muscle ...
Armand M. Frydman +11 more
openaire +2 more sources
Pharmacokinetics of rilmenidine
The American Journal of Cardiology, 1988Rilmenidine, an alpha 2-adrenoceptor agonist, was studied (1 mg single dose) in order to determine the effects of pathology on its basic pharmacokinetic parameters. Because of the mainly renal elimination of rilmenidine, studies involved hypertensive, elderly hypertensive, renal insufficient and hepatic insufficient patients.
E, Singlas +4 more
openaire +2 more sources
Developmental Pharmacokinetics
2011The advances in developmental pharmacokinetics during the past decade reside with an enhanced understanding of the influence of growth and development on drug absorption, distribution, metabolism, and excretion (ADME). However, significant information gaps remain with respect to our ability to characterize the impact of ontogeny on the activity of ...
Johannes N, van den Anker +2 more
openaire +2 more sources
Pharmacokinetics of methotrexate
Clinical Pharmacology & Therapeutics, 1974Methotrexate (Mtx) is a competitive inhibitor of the enzymatic activity of dihydrofolate reductase, decreasing the reduction of folic acid to tetrahydrofolate and thereby the activity of thymi dilate kinase. The net effect is a decrease in biosynthesis of deoxyribonucleic acid (DNA) primarily, but also of ribonucleic acid (RNA) and protein. Whereas the
D L, Azarnoff, S H, Wan, D H, Huffman
openaire +2 more sources
Seminars in Hematology, 2001
Despite the clinical use of deferoxamine for more than a quarter of a century, pharmacokinetic studies are few and have not been performed explicitly in patients with sickle cell disorders. Early studies with Intravenous administration to healthy volunteers and patients with transfusional overload showed that although peak concentrations of ...
openaire +2 more sources
Despite the clinical use of deferoxamine for more than a quarter of a century, pharmacokinetic studies are few and have not been performed explicitly in patients with sickle cell disorders. Early studies with Intravenous administration to healthy volunteers and patients with transfusional overload showed that although peak concentrations of ...
openaire +2 more sources